Pseudoephedrine 2006 Sales To Decline 35%, Perrigo Projects
This article was originally published in The Tan Sheet
Perrigo's fiscal 2006 pseudoephedrine sales will decrease 35% to the $110 mil. to $120 mil. range, the company projected during a 2005 year-end and fourth quarter analysts call Sept. 7
You may also be interested in...
Perrigo will not have a complete phenylephrine portfolio available to replace pseudoephedrine products until next year's cough/cold season, the company said during a fiscal 2006 first-quarter earnings call
The growing trend of limiting pseudoephedrine accessibility in stores is driving an expanding market for nasal decongestant alternatives containing phenylephrine
Perrigo's acquisition of Israeli generic drug firm Agis Pharmaceuticals will put the combined entity's annualized sales over the $1 bil. mark and in the same league with major Rx generic drug players